

Mitchell C Benson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9105041/publications.pdf>

Version: 2024-02-01

21
papers

1,530
citations

1039406

9
h-index

794141

19
g-index

22
all docs

22
docs citations

22
times ranked

2074
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 787.e9-787.e15.	0.8	9
2	Bladder Preservation for Patients With Bladder Paragangliomas: Case Series and Review of the Literature. <i>Urology</i> , 2020, 143, 194-205.	0.5	4
3	Oncologic outcomes of complete transurethral resection prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17029-e17029.	0.8	1
4	Reducing unnecessary biopsies while detecting significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 348.	0.8	1
5	Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. <i>Cell</i> , 2018, 173, 515-528.e17.	13.5	540
6	Oncologic Outcomes of Definitive Treatments for Low- and Intermediate-Risk Prostate Cancer After a Period of Active Surveillance. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e425-e435.	0.9	8
7	Urine Exosomes for Non-Invasive Assessment of Gene Expression and Mutations of Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0154507.	1.1	48
8	Predictors of biochemical recurrence in pT3b prostate cancer after radical prostatectomy without adjuvant radiotherapy. <i>Prostate</i> , 2016, 76, 226-234.	1.2	12
9	Natural history of clinical complete response to neoadjuvant chemotherapy for urothelial carcinoma of the bladder: Updated single-institution experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4537-4537.	0.8	1
10	Predictors of treatment outcomes following salvage intravesical chemotherapy in patients with prior BCG treatment.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16015-e16015.	0.8	0
11	Predicting Renal Parenchymal Loss after Nephron Sparing Surgery. <i>Journal of Urology</i> , 2015, 194, 658-663.	0.2	23
12	Phase II Trial of Intravesical Nanoparticle Albumin Bound Paclitaxel for the Treatment of Nonmuscle Invasive Urothelial Carcinoma of the Bladder after bacillus Calmette-GuÃ©rin Treatment Failure. <i>Journal of Urology</i> , 2014, 192, 1633-1638.	0.2	74
13	Who Really Benefits From Nephron-sparing Surgery?. <i>Urology</i> , 2014, 84, 860-868.	0.5	35
14	The impact of clinically significant discrepancies from primary pathological review of transurethral bladder resection specimens upon repeat review at a tertiary care center.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4552-4552.	0.8	1
15	BILATERAL INTRARENAL ADRENAL GLANDS IN CADAVERIC DONOR KIDNEYS RESEMBLING RENAL CELL CARCINOMA ON INTRAOPERATIVE FROZEN SECTION. <i>Journal of Urology</i> , 2001, 166, 1820-1821.	0.2	4
16	Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: Long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy. , 1999, 84, 360-364.		46
17	Reply to Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels. <i>Prostate</i> , 1998, 37, 138-139.	1.2	2
18	Percutaneous Approach to Treatment of Indiana Pouch Stones. <i>Journal of Urology</i> , 1994, 151, 690-692.	0.2	16

#	ARTICLE	IF	CITATIONS
19	Prostate Specific Antigen Density: A Means of Distinguishing Benign Prostatic Hypertrophy and Prostate Cancer. <i>Journal of Urology</i> , 1992, 147, 815-816.	0.2	669
20	The Flow Cytometric Analysis of Undescended Testes in Children. <i>Journal of Urology</i> , 1990, 144, 494-498.	0.2	9
21	Flow cytometric analysis of localized adenocarcinoma of the prostate: The use of archival DNA analysis in conjunction with pathological grading to predict clinical outcome following radical retropubic prostatectomy. <i>Prostate</i> , 1990, 17, 155-164.	1.2	27